Abstract: Angiotensin-converting enzyme (ACE) has been reported to show altered activity in patients with neurological diseases. The recent studies found that a 287 bp insertion/deletion (I/D) polymorphism of the ACE gene may be associated with susceptibility to Alzheimer's disease (AD) but the results have been heterogenous between studies in Europe. In the present study we examined for the first time the association of ACE I/D polymorphism along with APOE genotype in 70 sporadic AD and 126 control subjects in Slovak Caucasians (Central Europe). An increased risk for AD was observed in subjects with at least one APOE*E4 allele (OR=3.99, 95% CI=1.97-8.08). No significant differences for the genotype distribution or the allele frequency were revealed comparing controls and patients for ACE gene. Gene-gene interaction analysis showed increase of the risk to develop AD in subjects carrying both the ACE DD genotype and the APOE*E4 allele (OR=10.32, 95% C.I. 2.67-39.81).
Introduction
The genetic factors that predispose individuals to AD have not yet been fully defined. Having a first-degree relative with AD increases the risk for disease by approximately three-to fivefold [1, 2] . The APOE*E4 allele is the only genetic factor that is unequivocally associated with an increased risk of late-onset AD. The observation, that E4 is neither necessary nor sufficient to cause the disease has prompted the investigation of other candidate susceptibility genes. The possibility that genetic variation at the ACE locus may influence risk for AD is supported by several observations. Angiotensinconverting enzyme (ACE; dipeptidyl carboxypeptidase, EC 3.4.15.1) is a membrane-bound ectoenzyme. ACE is a very important component of the renin-angiotensin system (RAS) that acts in promoting formation of angiotensin II from angiotensin I and inactivating the vasodilatator bradykinin [3] . Angiotensin II plays an important role in blood pressure and sodium homeostasis [4] . Besides the classical RAS, a local RAS in the brain may play a critical role in the central nervous system. It has been reported that angiotensin in astrocytes is required for the functional maintenance of the blood brain barrier [5] , which is impaired in AD [6] . ACE activity in the cerebrospinal fluid and in the brain differs significantly between individuals with AD or in patients with mild cognitive impairment and healthy controls subjects [7] [8] [9] [10] . Finally, ACE has been demonstrated to inhibit amyloid-beta peptide aggregation and plaque formation in vitro [11] .
An insertion/deletion (I/D) polymorphism in intron 16 of the ACE gene on chromosome 17q23 has been identified resulting in three genotypes: homozygous DD, II and heterozygous ID [12] . A previous study of Tiret et al. [13] found, that I/D polymorphism of the ACE gene is associated with ACE level, and that subjects who carry the I allele have a lower ACE level than subjects bearing the D allele. The serum ACE activity of the DD genotype was twice as high as that of the ACE II genotype [14] . Arregui et al. [15] observed an increase in ACE activity in patients with AD.
Inconsistent results relating to association of ACE polymorphism to dementia between studies from North and South Caucasians as well as insufficient data from Middle Europe prompted us to investigate how ACE I/D polymorphism influences susceptibility to AD in Slovak population. 
Experimental procedures

Study population and sample processing
Genotyping assays
The genomic DNA was extracted from lymphocytes by Wizard Genomic DNA Extraction Kit (Promega). Genetic variation at the APOE locus has been performed by digesting the PCR product with the Afl III restriction enzyme as described by Chapman et al. [16] . The polymerase chain reaction (PCR) program for detection of ACE genotypes was performed according to the method of Ribichini et al. [17] . The sequences of the sense and antisense primers were 5´-CTG GAG ACC ACT CCC ATC CTT TCT-3´ and 5´-GAT GTG GCC ATC ACA TTC GTC AGA T-3´, respectively. PCR products were electrophoresed in 2% agarose gel and visualized directly with ethidium bromide staining. The insertion allele (I) was detected as a 490 bp band and the deletion allele (D) was detected as a 190 bp band. DMSO (dimethylsulfoxide) was included in the PCR to prevent underestimation of heterozygotes and overestimation of DD genotype [18] , moreover each DD genotype was subjected to a second independent PCR amplification with a primer pair that recognizes an insertion-specific sequence (5´-TGG GAC CAC AGC GCC CGC CAC TAC-3´; 5´-TCG CCA GCC CTC CCA TGC CCA TAA-3´), with identical PCR conditions except for an annealing temperature of 67°C and the absence of DMSO [19] . A PCR product of 287 bp has revealed the presence of the I allele in the examined samples.
Statistical analysis
The frequencies of genotypes and alleles were compared using the c 2 test or Fisher's exact test, as appropriate. A p-value of <0.05 was considered significant. The relative associations between genotypes and different type of dementia were assessed calculating Gart´s odds ratio (OR) and 95% confidence intervals (CI) using statistical software Arcus Quickstat Biomedical version 1.1. The two-by-four table approach was applied for gene-gene interactions analysis. # Mean ± SD *nonE4-none APOE*E4 allele **E4-at least one APOE*E4 allele
Results
We made a comparison of genotype distributions between control subjects and cases for both APOE and ACE ( Table 1) . As expected, a significant association was found for subjects with at least one APOE*E4 allele and AD (OR=3.99, 95% CI=1.97-8.08). The distribution of ACE genotypes was in HardyWeinberg equilibrium both in patients and in control subjects. There were no significant differences in either ACE allele or genotype frequency between cases and controls in the total samples. A significant interactive effect between APOE and ACE polymorphisms was found when comparing genotype two-combinations ( Table 2 ). The frequency of individuals with at least one E4 allele together with ACE DD genotype was overrepresented in the AD patients compared with controls (0.17 vs. 0.03, p=0.004). OR for carriers of APOE*E4 allele in combination with ACE DD genotype was 10.32, (95% C.I. 2.67-39.81) ( Table 3 ). The interaction analyses of other pairwise genotypes showed no significant effects with AD (p > 0.05; data not shown).
Discussion
Our results on APOE are consistent with evidence from other studies [20] [21] [22] [23] [24] [25] [26] regarding the significance of the E4-AD in relationship to the age spectrum (data not shown). Our study demonstrates no difference in ACE allele or genotype frequency between cases and controls in the total samples. The same results were found in Finnish study [27] , British study [28, 29] , Italian study [30] , and in Israeli Arab community [31] . In the papers by Amouyel et al. [32] , Palumbo et al. [33] , Zhang et al. [34] and Sleegers et al. [35] it has been evidenced that ACE*D allele represents a genetic susceptibility factor for cognitive impairment, independent of type of dementia.
Farrer et al. [26] found the association between AD and ACE*D allele among persons aged from 66 to 70 years. The ACE insertion-deletion polymorphism has also been implicated as a genetic risk factor for AD in a two recent meta-analyses. The first one [36] revealed the association of the I allele with an increased risk of late-onset AD, but the risk of AD appeared to be higher among Asians (OR=2,44; 95% C.I., 1,68 to 3,53) when compared with the risk among Caucasians (OR=1,18; 95% C.I., 1,02 to 1,37). Furthermore, heterogeneity between studies involving Caucasians from different geographic regions was significant (p < 0.001). On the other hand, Lehmann et al. [37] found an increased frequency of ACE ID heterozygotes in AD, II homozygotes showed no association and DD homozygotes were at reduced risk of AD (OR=0.81; 95% C.I. 0.72 to 0.90). There were obvious differences among the three ethnic groups examined (North Europeans, South Caucasians and East Asians).
In the present study, none of ACE genotypes were associated with increased susceptibility to AD in the total sample. It is clear, however, that negative findings for single polymorphism do not exclude the possible interactions with other loci. We found a significant interactive effect between APOE and ACE polymorphisms when combined genotype was assessed. Our results are not in conflict with conclusion of some other analyses. The principal component analysis disclosed that ACE*D and APOE*E4 alleles prevailed highly in the cognitively impaired groups subjects, namely LOAD patients [33] . Tian et al., [38] supposed that the APOE*E4 allele may act synergistically with ACE DD genotype in patients with AD (and other subjects) increasing the risk of myelin loss (ML), perhaps through transient ischaemic episodes consequent upon poor cardiac output associated with coronary atherosclerosis. The possible influence of APOE*E4 allele acting with ACE*D allele on the extent of white matter ML was assessed in an autopsy-confirmed AD patients. The highest mean ML severity score was seen in patients bearing the ACE DD.
The difference between meta-analysis dealing with ACE and our results may have several reasons. Our study group has limited size. The study was based on subjects from an Eastern part of Slovakia. The sample was therefore small, but cases and controls in our dataset were ethnically homogeneous and from the same geographic region. Alternative possible explanation of discrepancies is that an AD-ACE association may have been obscured by diagnostic heterogeneity in the case samples. Also ethnic difference may affect the observed results. The differences in ACE I/D and APOE allele frequencies were reported in the HIFMECH study and in previous studies on AD, which compared population from Northern and Southern Europe [39] [40] [41] . These studies established the geographical trend in ACE and APOE allele occurrence, decreasing in frequency from North to South for APOE*E4 and increasing in frequency from South to North for ACE*D allele. In the present study among subjects from Central Europe, the ACE allele and genotype frequencies of cognitively impaired individuals and controls were comparable to those from populations in England [42] , and in Italy [40] .
Discrepancies could be partly attributable to the fact that the ACE I/D polymorphism is in linkage disequilibrium with other multiple polymorphisms in the ACE gene that may account for the functional changes in ACE and thus increasing the risk for AD [43] . The pathophysiologic implications of the association between the ACE I/D polymorphism and AD can be properly understood if the gene-gene and gene-environment interactions will be studied further.
